LIke ThisLIke ThisLIke This

Lisa  Kenney, MD, MPH

Lisa Kenney
Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Medicine Research
Hematology/Oncology Research
Hospital Title:
Attending Physician
Academic Title:
Assistant Professor, Harvard Medical School
Research Focus Area:
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Kenney conducts clinical outcomes research focused on childhood cancer survivors. She is a principal investigator on the Childhood Cancer Survivors Study (CCSS) in the areas of second primary cancers and chronic disease. Dr Kenney is also the principal investigator on institutional clinical studies investigating male reproductive function, renal function, and gastrointestinal disease in childhood cancer survivors. Research interests also include investigating models of clinical services to address the ongoing medical needs of childhood cancer survivors.

About Lisa Kenney

Dr. Kenney received her MD at the State University of New York, Stony Brook School of Medicine, completed her Pediatric residency at Children's National Medical Center, Washington, DC and a pediatric hematology/oncology fellowship at Children's National Medical Center, Washington, DC. Focus of Research The goal of Dr. Kenney's research is to reduce morbidity associated with treatment of cancer during childhood by understanding the spectrum of treatment associated late effects and designing interventions to improve long term outcomes for survivors.

LIke ThisLIke ThisLIke This


Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more